
Blend Appoints CU Veteran Reva Rao as Head of Digital Transformation for Credit Unions
Rao brings over two decades of experience in financial services, with extensive leadership roles at prominent credit unions including Travis Credit Union and Golden 1 Credit Union. Her deep understanding of credit union operations and member-centric approach will be instrumental in driving Blend's mission to help credit unions deliver exceptional digital experiences.
This appointment comes at a pivotal time as Blend continues to expand its footprint in the credit union industry and consumer banking overall. Blend is trusted by hundreds of financial institutions, including seven of the top 10 credit unions in the United States, to improve member experience, drive revenue growth and reduce operational costs across digital deposit account opening, consumer lending, and mortgage loan origination. Rao will focus on helping Blend credit union customers and partners to build their competitive edge and develop strategies to position for stronger growth.
"We are honored to have Reva join the Blend team," said Nima Ghamsari, Co-founder and Head of Blend. "Her deep credit union expertise and proven leadership in digital transformation will be invaluable not only for Blend's continued growth, but more importantly, for the credit unions we serve as they work to deliver exceptional member experiences in an increasingly digital world."
Prior to joining Blend, Rao served as Chief Lending Officer at Travis Credit Union, where she led Consumer, Mortgage and Commercial lending for the $5+ billion institution. She previously held senior executive roles at Golden 1 Credit Union as Senior Vice President of Consumer Loans, overseeing lending strategies for California's largest credit union with over $20 billion in assets.
Rao's career spans leadership positions across the financial services spectrum, including roles at Wells Fargo, where she spent over 13 years in various capacities including Channel Business Manager, and at Prosper Marketplace as Head of Home Equity Marketing. She also held senior positions at JPMorgan Chase, Greenpoint Mortgage, and Citi, developing expertise in pricing analytics, risk management, and digital product development.
"Credit unions are at the forefront of member-centric banking, and they deserve technology partners who truly understand their unique challenges and opportunities," said Rao. "Blend's unified platform approach aligns perfectly with credit unions' needs to deliver seamless, personalized experiences across all banking products. I'm excited to find new ways to help credit unions leverage innovative technologies so they can continue to build and deepen member relationships."
Blend's platform delivers end-to-end digital journeys for loan origination, account opening, and consumer onboarding, with specialized solutions for mortgages, deposits, credit cards, personal loans, auto loans, and HELOCs. Last year, financial institutions processed nearly $1.2 trillion in loan applications through Blend's platform, demonstrating the company's robust capabilities and growing influence in financial services.
About Blend
Blend Labs Inc., (NYSE: BLND) is a leading digital origination platform for banks, credit unions, and mortgage lenders. From mortgages to consumer loans to deposit accounts, Blend helps financial institutions streamline workflows, launch faster, and deliver standout customer experiences. Learn more at blend.com.
Forward-Looking Disclaimer
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements generally relate to future events, future performance or expectations and involve substantial risks and uncertainties. Forward-looking statements in this press release may include, but are not limited to, our expectations regarding our product roadmap, future products/features, the timing of new product/feature introductions, market size and growth opportunities, macroeconomics and industry conditions, capital expenditures, plans for future operations, competitive position, technological capabilities and strategic relationships, as well as assumptions relating to the foregoing. The forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual outcomes to differ materially from the outcomes predicted. In some cases, you can identify forward-looking statements by terminology such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'would,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other comparable terminology that concern Blend's expectations, strategy, plans or intentions. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which such performance or results will be achieved, if at all. Further information on these risks and uncertainties are set forth in our filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Blend and assumptions and beliefs as of the date hereof. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except as required by law, Blend does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast
We recently published . Baxter International Inc. (NYSE:BAX) is one of the worst-performing stocks on Thursday. Baxter International dropped its share prices to a new 52-week low on Thursday, as investors soured on its lower earnings growth forecast. At intra-day trading, shares of Baxter International Inc. (NYSE:BAX) dropped to their lowest price of $21.47 before ending the day down by 22.42 percent at $21.76 apiece. In a call with analysts, Baxter International Inc. (NYSE:BAX) said it lowered its adjusted EPS to between $2.42 and $2.52 from the $2.47 to $2.55. Analysts expected $2.52 per share. 'While we never want to lower expectations, our overall objective is reducing the outlook to capture more of the potential downside risks,' Baxter International Inc. (NYSE:BAX) CFO Joel Grade was quoted as saying, underscoring the demand weakness for IV fluids. Pixabay / Public Domain In the second quarter of the year, Baxter International Inc. (NYSE:BAX) swung to a net income attributable to shareholders of $91 million from a $314 million net loss in the same period last year. Net sales inched up by 4 percent to $2.8 billion from $2.69 billion. While we acknowledge the potential of BAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
AB InBev (BUD) Sheds 13% as Investors Panic Over Declining Volumes
We recently published . Anheuser-Busch InBev SA/NV (NYSE:BUD) is one of the worst-performing stocks on Thursday. Anheuser-Busch dropped for a second day on Thursday, shedding 13.3 percent to close at $57.67 apiece as investor sentiment was dampened by declining volumes despite growing its earnings year-on-year. In its updated report, Anheuser-Busch InBev SA/NV (NYSE:BUD) said that beer and non-beer volumes declined by 1.9 percent in the second quarter of the year at 143,347 versus 146,302 in the same period last year amid weak industries and performance in China and Brazil. The first half of the year also saw total volumes dipping 2 percent to 279,615 from 285,837 in the same comparable period. Despite the volume drop, Anheuser-Busch InBev SA/NV (NYSE:BUD) still recorded a 13.8-percent jump in net income attributable to shareholders, to $1.676 billion from $1.472 billion in the same period last year, while revenues ended flat at $15 billion. Photo by Gio Bartlett on Unsplash In the first half, attributable net income increased by 49 percent to $3.8 billion from $2.56 billion year-on-year, while revenues decreased by 4.3 percent to $28.6 billion from $29.88 billion. While we acknowledge the potential of BUD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer
We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 18.3% year-to-date on the back of several factors, such as troubles in China and the expiration of its KEYTRUDA patents. Cramer's previous comments about the firm have praised the firm's deal with Verona, through which it will get access to a chronic pulmonary obstructive disease (COPD) treatment. The acquisition is important as investors have grown concerned about Merck & Co., Inc. (NYSE:MRK)'s drug pipeline and wondered whether future drugs will mimic KEYTRUDA's success. Cramer discussed these factors: 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' Later in the day, he commented on Merck & Co., Inc. (NYSE:MRK)'s earnings: 'What do we make of the numbers that we got from Merck this morning? The pharma titan reported what some thought was a mixed quarter. I actually liked it. Small revenue miss, paired with an 11-cent earnings beat. Stock got hit, finishing the day down nearly 2% although it was a lot lower at one point. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio